Apple to produce all new iPhone 17 models in India for first time: Report
In a boost to India's domestic manufacturing, the tech giant is also expanding iPhone 17 production across five factories, some of which are recently opened facilities, according to a report by Bloomberg.
Tata Group's plant in Hosur, Tamil Nadu, and Foxconn's production facility close to the Bengaluru airport, both of which recently became operational, will join existing units in producing the iPhone 17, as per the report.
This is the first time that Apple will produce and ship all new variations of an iPhone from India from the outset. The move comes as Apple looks to navigate the Trump administration's constantly shifting tariffs landscape by shifting the vast majority of the smartphone's production for the US market to India from China.
Tata's new plant joining iPhone 17 production also points to the conglomerate's potential role as a key partner of Apple. Tata Group is currently the only Indian company assembling iPhone 17s in the country, as Taiwan-based Foxconn has so far been Apple's leading contractor here.
In 2023, Tata bought Wistron Corp's Apple production plant located in Karnataka. It also owns a controlling stake in Pegatron's plant just outside of Chennai, Tamil Nadu. Tata-owned facilities are expected to contribute up to half of India's iPhone output over the next two years, as per the report.
The value of iPhone exports from India has grown substantially. The Indian Express had earlier reported that India's share in US smartphone imports surged to nearly 36 per cent in the first five months of 2025, from about 11 per cent in 2024. China, which continues to dominate the product category, saw its share drop from 82 per cent to 49 per cent over the same period.
In April, US President Donald Trump announced reciprocal tariffs on a number of countries, including India. Days later, the US exempted phones, computers and other electronic products from the reciprocal tariffs.
More recently, Trump slapped 50 per cent tariffs on India partly as a response to India's purchases of Russian oil. However, Apple's iPhones have so far emerged unscathed under exemptions. Earlier this month, Apple CEO Tim Cook announced a fresh commitment to invest $100 billion in the United States, with a particular focus on deepening its manufacturing base in the country.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Deccan Herald
6 minutes ago
- Deccan Herald
The rhetoric and real costs of trade wars
India misread the tariffs brought on by the United States and, at a broader level, the Trump administration. We were one of the first to approach the US on this matter, and we continued to believe that we would have a favourable deal till recently, given what we felt was a great rapport between Modi and Trump. Mainstream electronic media houses were complicit in driving this narrative. To understand why India got it wrong, it would be useful to connect two disparate data dots. Top that with India's misreading of Trump's desire to be seen as a look at the first irritant and its impact. India exports roughly $90 billion, paying approximately 2 per cent tariffs currently, and imports roughly $45 billion at 12 per cent tariffs. The trade deficit of $45 billion carries a tariff differential of $5 billion per year in India's favour after adjusting for exempted products. We should have seen this imbalance in America's trade deficit and tariffs long ago and proactively addressed this. Modi is now overhauling the tax rates in a bid to boost the economy. This is expected to cost $20 billion, four times the tariff differential India was enjoying. .The other irritant is oil imports. In 2021/22, India imported roughly 2.5 million barrels of oil every day. Under the tacit approval of the West, India's imports from Russia grew from 2 per cent then to 40 per cent today. India buys 45 per cent of the exported oil from Russia, a growth of 1900 per cent from pre-war levels. China buys the same percentage, a growth of 50 per cent from pre-war levels. So why did India need this extra oil suddenly? It was because we processed this extra oil and sold it for a profit overseas. Therefore, the rhetoric is misplaced, as we are profiting and fuelling the Russian war machine. Predicting the flow of events, we should have scaled down our offtake back to the 2022 levels and with that, justify our need to fuel the Indian economy and keep inflationary tendencies in check. We have now started to do this, drawing a balance between the US and predict that the impact of tariffs at 25 per cent is likely to be in the region of $11-12 billion per annum on tariffed goods and about 0.25 per cent on GDP. In the earliest days of cranking up our imports of oil, the difference was around $30 a barrel, leading to a gain of $16 billion. That has now come down to around $5 a barrel after accounting for logistics, etc. The benefit we get is estimated today to be only $3.5 billion, a delta of $8.5 billion from what we lose out on with the long commentators have suggested many responses, ranging from the knee-jerk to keeping the long-term in mind. The real issue is what we do now. There is no pattern in the madness. Why have the four treatments of the BRIC countries been different? Because there is a different playbook with each one. With Brazil, the US has a trade surplus. Why then, do they have tariffs of 50 per cent, which is higher than China and equal to India? Bolsonaro? With China, 150 per cent was brought down to 30 per cent; here, it is about the rare earths. For the quantities required, the ecosystem is expensive, and the returns don't work out for a commercial operation. The CCP subsidised this for leverage and their long-term plans to pursue electric mobility and clean energy. This leverage on supplies was used to resolve the $650 billion of trade at stake between the US and China. .India made public its hypocritical treatment at the hands of the US, as it bought palladium, uranium, etc. from Russia. However, the reality is that US imports from Russia were at best $3 billion, down some 45 per cent from the previous year. India's imports from Russia stood at $70 billion, almost twice what it imports from the must now not get caught in the whirlpool of its rhetoric. And it certainly must not seek to appease China and Russia in a hurry and on the rebound. One can expect that this is short-term. There are many moving parts – Russia and Ukraine could arrive at a truce as early as next month. India has already started to demonstrate it is willing to reduce its import of Russian oil while not displeasing Russia. The midterms in the US could go against Trump, and the US courts could reverse Trump's executive decisions. Importantly, Trump does not define the long-standing US relationship with India. Trump himself may not have a long-term view on this the US, it seems clear. The average tariff on its imports has seen inflows of $28 billion, three times post these levies were collected in June. This aggregates to $350 billion. Add to this DOGE cuts and some others, and we have $500 billion being saved or added to the US treasury. This pays half its annual interest cost of $1 trillion, which, if left alone, is not sustainable. This is good for no one, as it is the world's biggest market by the short term, one sees no harm in subtly managing the relationships and dynamics at play and being practical. In the long term, anyway, as economist John Maynard Keynes said, we are all dead..(The writer is the former managing director of a Tata Company and now runs a Bengaluru-headquartered corporate finance practice)
Economic Times
6 minutes ago
- Economic Times
Apple Watch update brings back blood oxygen tracking — here's what US users get
Apple Watch update brings back blood oxygen tracking for US users on Series 9, Series 10, and Ultra 2. The feature was earlier stopped due to a patent dispute. Now, users can easily check their blood oxygen levels with the Blood Oxygen app. Apple is also working on other health monitoring features like noninvasive glucose tracking. Tired of too many ads? Remove Ads Apple watch blood oxygen feature returns Tired of too many ads? Remove Ads Health tracking and future updates FAQs Apple is bringing back the blood oxygen monitoring feature on its newest Apple Watch models in the United States through a new software update. The update is available for Apple Watch Series 9, Series 10, and Apple Watch Ultra 2 With this update, US users can run oxygen level checks using the Blood Oxygen app, which collects data from the watch's sensors and shows it on a paired iPhone. The feature was previously disabled in the US due to regulatory and legal reasons. The return of the feature follows official approval from US authorities, as per the report by Game blood oxygen function was restricted earlier because of a patent dispute with Masimo, a medical technology company from Irvine, California. Masimo had accused Apple of misusing its pulse oximetry technology and hiring key Masimo staff after talks about a possible 2023, the US International Trade Commission (ITC) ruled in Masimo's favor, which temporarily blocked the import of Apple Watches with the contested feature. The ITC order only affected newly sold models in the US, so earlier Apple Watch owners and international users were not affected, as stated by Game first introduced blood oxygen tracking in the Apple Watch Series 6 in 2020, during the early days of the COVID-19 pandemic. Meanwhile, Masimo launched its own blood oxygen wearable, the W1 watch, in 2022. Apple temporarily removed the feature from new US models while appealing the ITC Apple confirmed that US Customs cleared the reintroduction of the feature through a redesigned software update. Beyond blood oxygen tracking, Apple is also working on broader health initiatives, including research on noninvasive glucose monitoring, as reported by Game Watch Series 9, Series 10, and Apple Watch Ultra 2 in the US now have the blood oxygen was removed due to a patent dispute with Masimo and regulatory restrictions, but now it is back.
Time of India
9 minutes ago
- Time of India
Apple Watch update brings back blood oxygen tracking — here's what US users get
Apple watch blood oxygen feature returns Live Events Health tracking and future updates FAQs (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel Apple is bringing back the blood oxygen monitoring feature on its newest Apple Watch models in the United States through a new software update. The update is available for Apple Watch Series 9, Series 10, and Apple Watch Ultra 2 With this update, US users can run oxygen level checks using the Blood Oxygen app, which collects data from the watch's sensors and shows it on a paired iPhone. The feature was previously disabled in the US due to regulatory and legal reasons. The return of the feature follows official approval from US authorities, as per the report by Game blood oxygen function was restricted earlier because of a patent dispute with Masimo, a medical technology company from Irvine, California. Masimo had accused Apple of misusing its pulse oximetry technology and hiring key Masimo staff after talks about a possible 2023, the US International Trade Commission (ITC) ruled in Masimo's favor, which temporarily blocked the import of Apple Watches with the contested feature. The ITC order only affected newly sold models in the US, so earlier Apple Watch owners and international users were not affected, as stated by Game first introduced blood oxygen tracking in the Apple Watch Series 6 in 2020, during the early days of the COVID-19 pandemic. Meanwhile, Masimo launched its own blood oxygen wearable, the W1 watch, in 2022. Apple temporarily removed the feature from new US models while appealing the ITC Apple confirmed that US Customs cleared the reintroduction of the feature through a redesigned software update. Beyond blood oxygen tracking, Apple is also working on broader health initiatives, including research on noninvasive glucose monitoring, as reported by Game Watch Series 9, Series 10, and Apple Watch Ultra 2 in the US now have the blood oxygen was removed due to a patent dispute with Masimo and regulatory restrictions, but now it is back.
